Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 58, Issue 2, 2012, Pages 191-199

  Houghton, Peter J ^a   Gorlick, Richard ^b   Kolb, E Anders ^c   Lock, Richard ^d   Carol, Hernan ^d   Morton, Christopher L ^e   Keir, Stephen T ^f   Reynolds, C Patrick ^g   Kang, Min H ^g   Phelps, Doris ^a   Maris, John M ^h   Billups, Catherine ^e   Smith, Malcolm A ⁱ  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^d CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ NCI   (United States)

Author keywords

Developmental therapeutics; MTOR inhibitor; Preclinical testing

Indexed keywords

AZD 8055; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN P; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; S6 KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME INHIBITION; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOID TUMOR; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CHILD; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MORPHOLINES; NEOPLASMS, EXPERIMENTAL; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 83455253885     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22935     Document Type: Article

References (34)

1. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
2. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009; 2: pe24.
3. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
4. Hall MN. mTOR-what does it do? Transplant Proc 2008; 40: S5-S8.
5. Dilling MB, Dias P, Shapiro DN, et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 1994; 54: 903-907.
6. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008; 50: 799-805.
7. Houchens DP, Ovejera AA, Riblet SM, et al. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 1983; 19: 799-805.
8. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
9. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
10. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
11. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007; 25: 4806-4812.
12. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508.
13. Shi Y, Yan H, Frost P, et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4: 1533-1540.
14. Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751, 871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009; 69: 7662-7671.
15. Persad S, Dedhar S. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev 2003; 22: 375-384.
16. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70: 288-298.
17. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023-8032.
18. Dilling MB, Germain GS, Dudkin L, et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002; 277: 13907-13917.
19. Dowling RJ, Topisirovic I, Alain T, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010; 328: 1172-1176.
20. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
21. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2007; 9999.
22. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharmaceut Statist 2010 [PubMed print], DOI: 10.1002/pst.426.
23. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988; 48: 4189-4195.
24. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
25. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
26. Kurmasheva RT, Harwood FC, Houghton PJ. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Molecular cancer therapeutics 2007; 6: 1620-1628.
27. Hegedus T, Orfi L, Seprodi A, et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002; 1587: 318-325.
28. Hamada A, Miyano H, Watanabe H, et al. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 2003; 307: 824-828.
29. Yokota A, Kimura S, Masuda S, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007; 109: 306-314.
30. Saraiya B, Gounder M, Dutta J, et al. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs 2008; 19: 411-420.
31. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174.
32. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
33. Breuleux M, Klopfenstein M, Stephan C, et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009; 8: 742-753.
34. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008; 68: 8039-8048.